BRPI0606606A2 - composições estáveis contendo prostaglandina - Google Patents

composições estáveis contendo prostaglandina

Info

Publication number
BRPI0606606A2
BRPI0606606A2 BRPI0606606-2A BRPI0606606A BRPI0606606A2 BR PI0606606 A2 BRPI0606606 A2 BR PI0606606A2 BR PI0606606 A BRPI0606606 A BR PI0606606A BR PI0606606 A2 BRPI0606606 A2 BR PI0606606A2
Authority
BR
Brazil
Prior art keywords
prostaglandin
containing compositions
acid ester
chemical stability
alkanoic acid
Prior art date
Application number
BRPI0606606-2A
Other languages
English (en)
Inventor
Victor Deaciuc
Michael Hagan
Hashem Heiati
Karem Kostick Jette
Gregory C Visor
Ian G C Mcaffer
Peter Tasko
Original Assignee
Breath Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Breath Ltd filed Critical Breath Ltd
Publication of BRPI0606606A2 publication Critical patent/BRPI0606606A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIçõES ESTáVEIS CONTENDO PROSTAGLANDINA. A presente invenção se refere à composição farmacêutica contendo uma prostaglandina e um éster de ácido alcanóico de um sorbitol polietoxilado em uma quantidade eficaz para intensificar a estabilidade química da prostaglandina e o uso da mesma para o tratamento de condições oftálmicas. Também divulgados são métodos para intensificação da estabilidade química de uma composição contendo prostaglandina através de uso de um éster de ácido alcanóico de um sorbitol polietoxilado.
BRPI0606606-2A 2005-01-20 2006-01-18 composições estáveis contendo prostaglandina BRPI0606606A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0501192.9A GB0501192D0 (en) 2005-01-20 2005-01-20 Stable prostaglandin-containing compositions
PCT/US2006/001626 WO2006078659A2 (en) 2005-01-20 2006-01-18 Stable prostaglandin-containing compositions

Publications (1)

Publication Number Publication Date
BRPI0606606A2 true BRPI0606606A2 (pt) 2009-07-07

Family

ID=34259405

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606606-2A BRPI0606606A2 (pt) 2005-01-20 2006-01-18 composições estáveis contendo prostaglandina

Country Status (16)

Country Link
US (2) US8084501B2 (pt)
EP (1) EP1843744A2 (pt)
JP (2) JP2008528490A (pt)
KR (1) KR20070094793A (pt)
CN (1) CN101106973A (pt)
AU (1) AU2006206649B2 (pt)
BR (1) BRPI0606606A2 (pt)
CA (1) CA2595237A1 (pt)
CZ (1) CZ2007555A3 (pt)
GB (1) GB0501192D0 (pt)
IL (1) IL184111A0 (pt)
IS (1) IS8665A (pt)
NO (1) NO20073699L (pt)
NZ (1) NZ556117A (pt)
WO (1) WO2006078659A2 (pt)
ZA (1) ZA200705428B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
CN101621997B (zh) 2007-01-26 2013-05-08 株式会社宝丽制药 医药组合物
US20100120908A1 (en) * 2007-02-07 2010-05-13 Teika Pharmaceutical Co., Ltd Eye drop preparation comprising latanoprost
JP2008247828A (ja) * 2007-03-30 2008-10-16 Wakamoto Pharmaceut Co Ltd ラタノプロストを含有する水性医薬組成物。
ES2394130T3 (es) 2007-11-30 2013-01-22 Toltec Pharmaceuticals, Llc Composiciones y métodos para tratar infecciones vaginales y biopelículas vaginales patógenas
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2328574A1 (en) * 2008-08-05 2011-06-08 University College Cork-National University of Ireland, Cork Treatment of retinal degeneration
US20100087540A1 (en) * 2008-10-07 2010-04-08 R-Tech Ueno, Ltd. Pharmaceutical composition
US20120232139A1 (en) * 2009-09-01 2012-09-13 Ryuji Ueno Composition for ocular topical administration treatment ocular hypertension and glaucoma
AU2010314863A1 (en) * 2009-11-09 2012-06-14 Allergan, Inc. Compositions for enhancing hair growth
TWI478730B (zh) * 2009-12-03 2015-04-01 Alcon Res Ltd 眼科乳劑
WO2012141334A1 (en) * 2011-04-12 2012-10-18 R-Tech Ueno, Ltd. Aqueous ophthalmic composition
DE102011108948A1 (de) * 2011-07-29 2013-01-31 Achim Göpferich Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen
CN104208015A (zh) * 2013-05-29 2014-12-17 天津金耀集团有限公司 含有曲伏***素和防腐剂的眼部制剂
EP3103439B1 (en) * 2015-06-09 2019-08-07 MEDproject Pharma-Entwicklungs- und Vertriebsgesellschaft mbH Drippable ophthalmic bimatoprost gel
EP3643297A4 (en) 2017-06-22 2021-03-17 Yonsung Fine Chemical Co., Ltd. OPHTHALMIC COMPOSITION FOR GLUCOMA TREATMENT
EP4331600A1 (en) * 2021-04-30 2024-03-06 Innovent Biologics (Suzhou) Co., Ltd. Oxm3 storage agent, oxm3 preparation, and preparation method

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1366215A (en) * 1916-08-05 1921-01-18 Vaporackumulator Ab Supplementary power plant for electric centrals
US5165918A (en) * 1988-06-28 1992-11-24 Ciba-Geigy Corporation Antimicrobial ophthalmic solutions containing dodecyl-dimethyl-(2 phenoxyethyl)-ammonium bromide and methods of using the same
ES2067864T3 (es) * 1990-05-22 1995-04-01 R Tech Ueno Ltd Tratamiento de la hipertension ocular con una combinacion sinergica para administracion ocular.
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5545665A (en) 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
SE9702681D0 (sv) 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
AU9305898A (en) 1997-09-09 1999-03-29 Procter & Gamble Company, The A process for making prostaglandin f analogs
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
WO2000020386A1 (en) 1998-10-05 2000-04-13 Alcon Laboratories, Inc. Stannane synthesis of prostanoids
US6417228B1 (en) * 1998-11-02 2002-07-09 Alcon Manufacturing, Ltd.. 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
SE9900025D0 (sv) 1999-01-08 1999-01-08 Synphora Ab Method and composition for treatment of female sexual dysfunction
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
DK1321144T3 (da) * 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
AR035541A1 (es) * 2000-11-13 2004-06-16 Pharmacia Ab Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
NO317079B1 (no) * 2002-08-02 2004-08-02 Maritime Hydraulics As Stigerorstrekkanordning
US6864282B2 (en) * 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
US20040076678A1 (en) * 2002-08-21 2004-04-22 Sucampo Ag Opthalmic solution
KR101253941B1 (ko) 2002-09-09 2013-04-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
AU2006206649B2 (en) 2010-05-27
CN101106973A (zh) 2008-01-16
WO2006078659A3 (en) 2006-11-16
WO2006078659A2 (en) 2006-07-27
ZA200705428B (en) 2008-09-25
EP1843744A2 (en) 2007-10-17
US20060270735A1 (en) 2006-11-30
AU2006206649A1 (en) 2006-07-27
JP2013056948A (ja) 2013-03-28
JP2008528490A (ja) 2008-07-31
KR20070094793A (ko) 2007-09-21
WO2006078659A8 (en) 2007-08-30
IS8665A (is) 2007-08-02
CA2595237A1 (en) 2006-07-27
NO20073699L (no) 2007-10-19
IL184111A0 (en) 2007-10-31
CZ2007555A3 (cs) 2007-10-10
US20120065258A1 (en) 2012-03-15
US8084501B2 (en) 2011-12-27
NZ556117A (en) 2009-10-30
GB0501192D0 (en) 2005-03-02

Similar Documents

Publication Publication Date Title
BRPI0606606A2 (pt) composições estáveis contendo prostaglandina
BRPI0507198A (pt) derivados de bisariluréia
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
NI201000022A (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
DE60325379D1 (de) Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
BR112012021771A2 (pt) métodos de uso de inibidores de contransportadores de sódio-glicose 1 e 2.
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
BRPI0514766A (pt) composições farmacêuticas
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
BR112015010908A2 (pt) derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo
BR0113989A (pt) Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos
CR10479A (es) Modulares bencimidazolicos de vr1
PA8783401A1 (es) Derivados de piperidina/piperazina
ECSP10010167A (es) Composiciones oftálmicas novedosas
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
DK1797088T3 (da) Hidtil ukendte chromen-2-on-derivater og anvendelse heraf som monoamin-neurotransmitter-genoptagelseshæmmere

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.